SUPPLEMENTARY MATERIAL

Silver(I)-Catalyzed Addition of Zirconocenes to Epoxy Esters: A New Entry to 1,4-Dicarbonyl Compounds and Pyridazinones


Peter Wipf* and Joey-Lee Methot

Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, U.S.A.


Experimental parts. ¹H and ¹³C NMR spectra for all new compounds.

P. Wipf, J. Methot


General: All reactions were performed in flame-dried or oven-dried glassware under a dry nitrogen atmosphere. THF and ether were distilled over Na/benzophenone, while CH_2CH_2 was distilled over CaH_2 . Hexane, EtOAc and TMSCI were distilled prior to use. All other reagents and solvents were used as received unless otherwise noted. Analytical thin layer chromatography was performed on pre-coated silica gel 60 F-254 plates available from Merck. Flash chromatography was performed using silica gel 60 (230-400 mesh) available from Baker. NMR spectra were recorded in CDCl₃ (or unless otherwise noted) at either 300 MHz (¹H NMR) or 75 MHz (¹³C NMR) using Bruker Avance 300 with XWIN-NMR software. Chemical shifts (δ) are expressed relative to tetramethylsilane. IR spectra were obtained on a Nicolet Avatar 360 FT-IR, optical rotations were measured on a Perkin-Elmer 241 polarimeter, and mass spectra were obtained on a VG-70-70 HF.



But-2-enedioic acid ethyl ester 2-methyl-oxiranylmethyl ester (4). A solution of monoethyl fumarate (7.50 g, 52.0 mmol) in 100 mL of CH2CI2 was cooled to 0 °C and 600 mg (4.91 mmol) of DMAP was added followed by 2-methyl-2-propen-1-ol (5.00 mL, 59.4 mmol) and DCC (12.0 g, 58.2 mmol). After 1 h the reaction mixture was warmed to room temperature and stirred for another 11 h. Filtration of the byproducts, concentration, and chromatography on SiO₂ (hexane/EtOAc, 20:1) yielded 9.51 g (92%) of the diester which was redissolved in 100 mL of CH₂Cl₂. At 0 °C, mCPBA (16.57 g; 48.0 mmol assuming 50% purity) was added portionwise. After 3 h the cooling bath was removed and stirring was continued for 9 h. The suspension was treated with 1.5 M Na₂S₂O₅, stirred for 90 min, and the organic layer was washed with 2 N NaOH. The solution was dried (Na_2SO_4) , filtered, and concentrated to give 10.05 g (90% based on monoethyl fumarate) of oily 4: IR (neat) 2985, 2941, 1722, 1390, 1376, 1303, 1264, 1228, 1157, 1033, 984 cm⁻¹; ¹H NMR δ 6.93 (s, 2 H), 4.41 (d, 1 H, J = 12.0 Hz), 4.30 (q, 2 H, J = 7.1 Hz), 4.12 (d, 1 H, J = 12.0 Hz), 2.84 (d, 1 H, J = 4.7 Hz), 2.74 (d, 1 H, J = 4.7 Hz), 1.45 (s, 3 H), 1.36 (t, 3 H, J = 7.1 Hz); ¹³C NMR δ 164.6, 164.4, 134.3, 132.8, 67.9, 61.3, 54.5, 51.7, 18.3, 14.0; MS (EI) m/z (rel intensity) 169 (M⁺, 0.3), 155 (0.3), 145 (1), 141 (2), 138 (2), 127 (100), 99 (6), 82 (5), 71 (7), 55 (12); HRMS (EI) m/z calculated for $C_{10}H_{14}O_5$ 169.0501, found 169.0504.



General procedure A for alkenylzirconocene addition to 4 (5a-d). (2SR,4SR)-3-[(2-Hex-1-(E)-enyl)-4-hydroxymethyl-4-methyl-[1,3]dioxolan-2-yl)]-acrylic acid ethyl ester (5a). A solution of 110 mg (1.34 mmol) of 1-hexyne in 7 mL of CH₂Cl₂ was treated portionwise with 366 mg (1.43 mmol) of Cp₂ZrHCl¹ and stirred for 20 min. At 0 °C, the epoxy-ester **4** (212 mg, 0.991 mmol) was added via syringe followed by $P(OPh)_3$ (22 mg, 0.071 mmol, 0.05 eq.) and 20 wt% AgCIO₄/Celite (74 mg, 0.072 mmol Ag(I), 0.05 eq.). After stirring at room temperature overnight, the mixture was diluted with 5 mL of CH₂Cl₂, filtered through a plug of SiO₂, washed twice with 10% HCl and then twice with saturated NaHCO₃. The organic layer was dried (MgSO₄), filtered, and concentrated. Chromatography on SiO₂ (hexane/EtOAc, 4:1) provided recovered epoxy-ester 4 (17 mg; 8%) and 215 mg (73%) of oily 5a as a single diastereomer: IR (neat) 3491, 2958, 2931, 2874, 1723, 1664, 1466, 1392, 1369, 1302, 1268, 1176, 1123, 1039, 978 cm^{-1} ; ¹H NMR δ 6.81 (d, 1 H, J = 15.5 Hz), 6.10 (d, 1 H, J = 15.7 Hz), 5.87 (dt, 1 H, J = 15.6 Hz), 5.49 (d, 1 H, J = 15.7 Hz), 4.19 (q, 2 H, J = 7.1 Hz), 4.01 (d, 1 H, J = 8.4 Hz), 3.62 (d, 1 H, J = 8.4 Hz), 3.47-3.56 (m, 2 H), 2.25-2.15 (br, 1H), 2.03 (q, 2 H, J = 6.7 Hz), 1.22-1.37 (m, 10 H), 0.86 (t, 3 H, J = 7.0 Hz); ¹³C NMR δ 166.4, 146.5, 134.7, 128.5, 121.5, 107.0, 82.7, 71.7, 67.3, 60.8, 31.8, 30.9, 22.3, 21.4, 14.3, 14.0; MS (EI) *m/z* (rel intensity) 298 (M⁺, 2), 267 (57), 253 (20), 225 (100), 215 (20), 199 (45), 193 (25), 137 (62), 130 (55), 111 (43), 71 (44), 55 (52); HRMS (EI) m/z calculated for C₁₆H₂₆O₅ 298.1780, found 298.1769.




(2SR, 4SR)-3-[2-(5-Benzyloxy-pent-1-(*E*)-enyl))-4-hydroxymethyl-4-methyl-[1,3]dioxolan-2-yl)]-acrylic acid ethyl ester (5b). According to general procedure A, 587 mg (2.74 mmol) of epoxy ester 4 and 530 mg (3.04 mmol) of *O*-benzyl-1-pentynol provided recovered 4 (70 mg, 12%) and 736 mg (69%) of oily 5b as a single diastereomer: IR (neat) 3473, 2979, 2935, 2871, 1720, 1661, 1454, 1367, 1301, 1268, 1175, 1099, 1039, 978 cm⁻¹; ¹H NMR δ 7.35-7.25 (m, 5 H), 6.83 (d, 1 H, *J* = 15.7 Hz), 6.13 (d, 1 H. *J* = 15.5 Hz), 5.92 (dt, 1 H, *J* = 15.7,

^{1.} Buchwald, S. L.; La Maire, S. J.; Nielson, R. B.; Watson, B. T.; King, S. M. Tetrahedron Lett. 1987, 28, 3895.


6.7 Hz), 5.53 (d, 1 H, J = 15.6 Hz), 4.49 (s, 2 H), 4.22 (q, 2 H, J = 7.1 Hz), 4.02 (d, 1 H, J = 8.4 Hz), 3.64 (d, 1 H, J = 8.3 Hz), 3.5-3.4 (m, 4 H), 2.17 (dt, 2 H, J = 7.1, 6.6 Hz), 2.1-2.0 (m, 1H), 1.75-1.66 (m, 2 H), 1.34-1.24 (m, 6 H); ¹³C NMR δ 166.4, 146.4, 138.6, 133.8, 129.1, 128.5, 127.8, 127.7, 121.6, 106.9, 82.8, 73.0, 71.7, 69.6, 67.2, 60.8, 28.9, 21.5, 14.3; MS (EI) *m/z* (rel intensity) 390 (M⁺, 0.1), 359 (0.5), 345 (2), 317 (14), 291 (6), 130 (14), 91 (100), 84 (34), 71

(22); HRMS (EI) m/z calculated for C₂₂H₃₀O₆ 390.2042, found 390.2046.



(2SR,4SR)-3-[2-(3-Benzyloxy-but-1-(E)-enyl)-4-hydroxymethyl-4-methyl-


[1,3]dioxolan-2-yl)]-acrylic acid ethyl ester (5c). According to general procedure A with an additional 3 mol% Ag(I) added after 4 h, 225 mg (1.05 mmol) of **4** and 200 mg (1.25 mmol) of *O*-benzyl-3-butyn-2-ol gave 95 mg (42%) of recovered **4** and 122 mg (31%) of oily **5c** as a ca. 10:1 mixture of diastereomers. Major diastereomer: IR (neat) 3432, 2977, 2917, 2871, 2849, 1722, 1659, 1651, 1454, 1369, 1303, 1274, 1177, 1112, 1038 cm⁻¹; ¹H NMR & 7.33-7.25 (m, 5 H), 6.85 (d, 1 H, J = 15.7 Hz), 6.16 (d, 1 H. J = 15.6 Hz), 5.92 (dd, 1 H, J = 15.7, 6.7 Hz), 5.72 (d, 1 H, J = 15.9 Hz), 4.54 (d, 1 H, J = 11.8 Hz), 4.39 (d, 1 H, J = 11.9 Hz), 4.23 (q, 2 H, J = 7.1 Hz), 4.04 (d, 1 H, J = 8.3 Hz), 3.99 (m, 1 H, J = 6.5 Hz), 3.67 (d, 1 H, J = 8.3 Hz), 3.55, 3.49 (AB, 2H, J = 11.3 Hz), 2.0-1.9 (bm, 1H), 1.35-1.27 (m, 9 H); ¹³C NMR δ 166.3, 145.9, 138.5, 135.2, 130.0, 128.5, 127.8, 121.9, 106.7, 83.0, 74.7, 71.7, 70.4, 67.1, 60.9, 21.5, 21.4, 14.3; MS (EI) *m/z* (rel intensity) 376 (M⁺, 0.2), 361 (0.6), 347 (0.3), 331 (8), 303 (15), 285 (29), 270 (16), 241 (30), 215 (25), 189 (17), 182 (17), 153 (17), 127 (24), 91 (100); HRMS (EI) *m/z* calculated for $C_{19}H_{23}O_5$ [M-OCH₂CH₃] 331.1545, found 331.1543.




(2*SR*,4*SR*)-3-{2-[4-(2,2-Dimethyl-propionyloxy)-but-1-(*E*)-enyl]-4-hydroxymethyl-4-methyl-[1,3]dioxolan-2-yl)-acrylic acid ethyl ester (5d). According to general procedure A, 190 mg (0.888 mmol) of 4 and 125 mg (0.811 mmol) of *O*-pivaloyl-3-butynol provided 198 mg (66%) of oily 5d as a single diastereomer: IR (neat) 3435, 2978, 2930, 2875, 1726, 1660, 1481,

Page 5

1368, 1302, 1161, 1039 cm⁻¹; ¹H NMR δ 6.81 (d, 1 H, *J* = 15.5 Hz), 6.12 (d, 1 H. *J* = 15.6 Hz), 5.89 (dt, 1 H, *J* = 15.7, 6.8 Hz), 5.61 (d, 1 H, *J* = 15.6 Hz), 4.21 (q, 2 H, *J* = 7.1 Hz), 4.12 (t, 2 H, *J* = 6.3 Hz), 4.03 (d, 1 H, *J* = 8.4 Hz), 3.65 (d, 1 H, *J* = 8.3 Hz), 3.54, 3.48 (AB, 2H, *J* = 11.3 Hz), 2.39 (dt, 2 H, *J* = 6.5, 5.5 Hz), 2.0-1.8 (bm, 1 H), 1.32-1.27 (m, 6 H), 1.17 (s, 9 H); ¹³C NMR δ 178.6, 166.3, 146.2, 131.2, 129.6, 121.7, 106.7, 82.9, 71.7, 67.3, 62.9, 60.8, 38.9, 31.6, 27.3, 21.5, 14.3; MS (EI) *m/z* (rel intensity) 370 (M⁺, 1), 324 (6), 296 (16), 236 (46), 194 (35), 180 (16), 168 (27), 129 (24), 106 (55), 81 (33), 71 (29), 57 (100); HRMS (EI) *m/z* calculated for C₁₉H₃₀O₇ 370.1992, found 370.2005.



General procedure B for the conjugate addition to dialkenyl acetals (6a-c, 6e-f). 3-Methyl-4-oxo-dec-5-enoic acid ethyl ester (6a). A suspension of CuBr•SMe₂ (1.13 g, 5.50 mmol) in 20 mL of THF at -78 °C was treated with 7.9 mL (11.1 mmol) of a 1.4 M solution of MeLi in ether. The reaction mixture was warmed to -20 °C and stirred until colorless. At -78 °C, 0.70 mL (5.52 mmol) of TMSCI was added followed by a precooled solution of 5a (549 mg, 1.84 mmol) in 2 mL of THF. Over a 30 min period the temperature was raised to -25 °C and the solution was stirred at that temperature for another 20 min before being guenched by dropwise addition of 4 mL of 10% HCI. The mixture was diluted with EtOAc, and washed with 10% HCl and saturated NaHCO₃. The organic layer was concentrated, dissolved in 20 mL of acetone/H₂O (9:1), and treated with TsOH (70 mg, 0.37 mmol). The reaction mixture was heated at reflux for 6 h, concentrated to 5 mL, poured into saturated NaHCO₃ solution, and extracted with EtOAc. The combined organic layers were dried (MgSO₄), filtered and concentrated. Chromatography on SiO₂ (hexane/EtOAc, 20:1) gave 398 mg (96%) of oily 6a: IR (neat) 2967, 2931, 2872, 1735, 1695, 1673, 1630, 1184 cm⁻¹; ¹H NMR δ 6.89 (dt, 1 H, J = 15.7, 7.1 Hz), 6.13 (dt, 1 H, J = 15.6, 1.4 Hz), 4.06 (q, 2 H, J = 7.1 Hz), 3.28-3.12 (m, 1 H), 2.74 (dd, 1 H, J = 16.6, 8.3 Hz), 2.30-2.15 (m, 3 H), 1.45-1.20 (m, 4 H), 1.20 (t, 3 H, J = 7.1 Hz), 1.10 (d, 3 H, J = 7.2 Hz), 0.89 (t, 3 H, J = 7.1 Hz); ¹³C NMR δ 201.9, 172.3, 148.1, 128.5, 60.4, 39.7, 37.0, 32.2, 30.2, 22.3, 17.1, 14.1, 13.8; MS (EI) *m/z* (rel intensity) 226 (M⁺, 8), 199 (5), 181 (20), 165 (3), 143 (14), 125 (15), 111 (100), 95 (12), 84 (12), 68 (15), 55 (67); HRMS (EI) m/z calculated for C13H22O3 226.1569, found 226.1562.



268.2037.


3-Butyl-4-oxo-dec-5-enoic acid ethyl ester (6b). According to general procedure B, 500 mg (1.68 mmol) of acetal **5a** and Bu₂CuLi (4.8 eq.) provided 401 mg (89%) of ketoester **6b** as an oil: IR (neat) 2958, 2930, 2872, 2861, 1736, 1695, 1670, 1628, 1178 cm⁻¹; ¹H NMR δ 6.89 (dt, 1 H, *J* = 15.7, 7.0 Hz), 6.16 (dt, 1 H, *J* = 15.7, 1.5 Hz), 4.06 (q, 2 H, *J* = 7.1 Hz), 3.25-3.15 (m, 1 H), 2.74 (dd, 1 H, *J* = 16.7, 9.3 Hz), 2.34 (dd, 1 H, *J* = 16.7, 4.9 Hz), 2.25-2.15 (m, 2 H), 1.65-1.50 (m, 1 H), 1.46-1.17 (m, 13 H), 0.89 (t, 3 H, *J* = 7.2 Hz), 0.84 (t, 3 H, *J* = 7.1 Hz); ¹³C NMR δ 202.0, 172.4, 147.8, 129.4, 60.4, 44.7, 35.4, 32.1, 31.6, 30.1, 29.0, 22.6, 22.2, 14.1, 13.8; MS (EI) *m/z* (rel intensity) 268 (M⁺, 8), 223 (41), 212 (43), 185 (5), 166 (5), 139 (5), 111 (100), 84 (14), 69 (13), 68 (12); HRMS (EI) *m/z* calculated for C₁₆H₂₈O₃ 268.2038, found

EtO Ph O 6c

4-Oxo-3-phenethyl-dec-5-enoic acid ethyl ester (6c). According to general procedure B, 170 mg (0.570 mmol) of acetal **5a** and (PhCH₂CH₂)₂CuLi² (4.9 eq.) gave 165 mg (92%) of oily **6c**: IR (neat) 2957, 2930, 2861, 1735, 1694, 1668, 1627, 1455, 1372, 1182, 1113 cm⁻¹; ¹H NMR δ 7.30-7.13 (m, 5 H), 6.84 (dt, 1 H, *J* = 15.7, 6.8 Hz), 4.09 (q, 2 H, *J* = 7.1 Hz), 3.27-3.24 (m, 1 H), 2.82 (dd, 1 H, *J* = 16.5, 9.2 Hz), 2.59 (t, 2 H, *J* = 8.0 Hz), 2.43 (dd, 1 H, *J* = 16.5, 5.0 Hz), 2.25-2.18 (m, 2 H), 2.0-1.9 (m, 1 H), 1.8-1.7 (m, 1 H), 1.5-1.3 (m, 4 H), 1.23 (t, 3 H, *J* = 7.1 Hz), 0.89 (t, 3 H, *J* = 7.3 Hz); ¹³C NMR δ 201.9, 172.4, 148.6, 141.3, 129.5, 128.6, 128.5, 126.2, 60.7, 44.2, 35.6, 33.7, 33.2, 32.4, 30.3, 22.4, 14.3, 14.0; MS (EI) *m/z* (rel intensity) 316 (M⁺, 3), 271 (20), 212 (100), 187 (40), 166 (34), 139 (50), 117 (24), 111 (52), 91 (97), 55 (95); HRMS (EI) *m/z* calculated for C₂₀H₂₈O₃ 316.2038, found 316.2025.




^{2.} Preparation of PhCH₂CH₂Li: Bailey, W. F.; Punzalan, E. R. J. Org. Chem. **1990**, *55*, 5404.




General procedure C for bisfunctionalization of dialkenyl acetals (6d, 6g). 2-Benzyloxymethyl-3-methyl-4-oxo-dec-5-enoic acid ethyl ester (6d). A suspension of CuBr•SMe₂ (648 mg, 3.15 mmol) in 3 mL of THF was treated at -78 °C with 4.50 mL (6.30 mmol) of a 1.4 M solution of MeLi in ether. The reaction mixture was slowly warmed to -20 °C, stirred 30 min and then recooled to -78 °C. Subsequently, TMSCI (1.00 mL, 7.88 mmol) was added followed by a solution of acetal 5a (180 mg, 0.604 mmol) in 1 mL of THF. The temperature was raised to -30 °C and the reaction mixture was stirred for 2 h before guenching with saturated NH₄CI. The mixture was diluted with 5 mL of ether and the organic layer washed with 10% HCl and 2 N NaOH, dried (MgSO₄), filtered, and concentrated. The residue was dissolved in 3 mL of CH₂Cl₂ and treated with imidazole (100 mg, 1.47 mmol) and TBSCI (140 mg, 0.933 mmol). After stirring for 10 h, the mixture was washed with 10% HCl and saturated NaHCO₃, dried (MgSO₄), filtered, concentrated and chromatographed on SiO₂ (hexane/EtOAc, 9:1) to provide 230 mg (89%) of the intermediate protected acetal: ¹H NMR δ 5.76 (dt, 1 H, J = 15.5, 7.0 Hz), 5.37 (dd, 1 H, J = 15.7, 1.4 Hz), 4.13 (q, 2 H, J = 7.1 Hz), 3.88-3.84 (m, 1 H), 3.64-3.43 (m, 3 H), 2.63 (dd, 1 H, J = 15.2, 4.5 Hz), 2.3-2.2 (m, 1 H), 2.1-1.95 (m, 3 H), 1.4-1.2 (m, 10 H), 0.97-83 (m, 15 H), 0.03 (m, 6 H).


A solution of this acetal (65 mg, 0.152 mmol) in 1 mL of THF was treated at -78 °C with 2.0 M LDA in heptane/THF/ethylbenzene (0.100 mL, 0.200 mmol), warmed slowly (30 min) to -30 °C, and recooled to -78 °C. After addition of PhCH₂OCH₂CI (30 µL, 0.216 mmol), the cooling bath was removed and after 3 h the solution was diluted with 3 mL of ether and washed with 10% HCI and saturated NaHCO₃ solution. The mixture was concentrated and redissolved in 5 mL of acetone/water (4:1). TsOH was added (3 mg, 0.016 mmol) and the mixture was heated at reflux for 6 h, diluted with ether, washed with 10% HCl and saturated NaHCO₃ solution, and dried (MgSO₄). Filtration, concentration and chromatography on SiO₂ (hexane/EtOAc, 20:1) provided 40 mg (76%) of 6d as an oil: IR (neat) 2959, 2931, 2873, 1734, 1694, 1669, 1627, 1455, 1374, 1181, 1106 cm⁻¹; ¹H NMR δ 7.33-7.24 (m, 5 H), 6.89 (dt, 1 H, J = 15.9, 6.9 Hz), 6.20-6.09 (m, 1 H), 4.5-4.4 (m, 2 H), 4.2-4.1 (m, 2 H), 3.8-3.5 (m, 2 H), 3.15-3.05 (m, 2 H), 2.19 (dt, 2 H, J = 7.2 Hz), 1.45-1.15 (m, 7 H), 1.15-1.05 (m, 3 H), 0.90 (t, 3 H, J = 6.7 Hz); ¹³C NMR δ 201.4, 173.1, 148.6, 148.0, 138.1, 129.0, 128.9, 128.3, 127.5, 73.2, 73.0, 69.5, 67.9, 60.7, 48.4, 47.5, 42.4, 41.4, 32.3, 30.2, 22.3, 15.4, 14.6, 14.3, 13.9; MS (EI) m/z (rel intensity) 346 (M⁺, 2), 301 (5), 239 (6), 225 (4), 207 (9), 183 (5), 140 (50), 111 (55), 91 (100), 55 (35); HRMS (EI) *m/z* calculated for C₂₁H₃₀O₄ 346.2144, found 346.2146.




9-Benzyloxy-3-methyl-4-oxo-non-5-enoic acid ethyl ester (6e). According to general procedure B, 144 mg (0.369 mmol) of acetal **5b** and Me₂CuLi (4.9 eq.) provided 114 mg (97%) of **6e** as an oil: IR (neat) 2977, 2934, 2857, 1734, 1695, 1670, 1628, 1455, 1268, 1185, 1103, 1029 cm⁻¹; ¹H NMR δ 6.93 (dt, 1 H, *J* = 15.7, 6.9 Hz), 6.18 (d, 1 H, *J* = 15.7 Hz), 4.50 (s, 2 H), 4.10 (q, 2 H, *J* = 7.1 Hz), 3.50 (t, 2 H, *J* = 6.3 Hz), 3.28-3.18 (m, 1 H), 2.78 (dd, 1 H, *J* = 16.6, 8.3 Hz), 2.38-2.27 (m, 3 H), 1.84-1.75 (m, 1 H), 1.23 (t, 3 H, *J* = 7.1 Hz), 3.12 (d, 3 H, *J* = 7.2 Hz); ¹³C NMR δ 202.1, 172.5, 147.5, 138.5, 128.8, 128.5, 127.8, 73.1, 69.4, 60.6, 39.9, 37.1, 29.4, 28.3, 17.3, 14.3; MS (EI) *m/z* (rel intensity) 318 (M⁺, 7), 273 (4), 247 (1), 227 (3), 203 (5), 160 (15), 143 (20), 138 (18), 91 (100); HRMS (EI) *m/z* calculated for C₁₉H₂₆O₄ 318.1831, found 318.1798.




7-Benzyloxy-3-butyl-4-oxo-oct-5-enoic acid ethyl ester (6f). According to general procedure B, 100 mg (0.266 mmol) of acetal **5c** with Bu₂CuLi (4.7 eq.) yielded 76 mg (82%) of **6f** as an oil: IR (neat) 2958, 2931, 2861, 1734, 1697, 1673, 1633, 1455, 1372, 1346, 1180, 1099 cm⁻¹; ¹H NMR (333 K) δ 7.35-7.27 (m, 5 H), 6.81 (dd, 1 H, *J* = 15.9, 5.9 Hz), 6.37 (dt, 1 H, *J* = 15.9, 0.9 Hz), 4.61-4.47 (m, 2 H), 4.17-4.07 (m, 3 H), 3.25-3.15 (m, 1 H), 2.76 (dd, 1 H, *J* = 16.4, 8.4 Hz), 2.38 (dd, 1 H, *J* = 16.5, 5.4 Hz), 1.7-1.6 (m, 1 H), 1.5-1.4 (m, 1 H), 1.4-1.2 (m, 10 H), 0.90 (t, 3 H, *J* = 6.7 Hz); ¹³C NMR δ 202.2, 172.6, 147.6, 138.2, 128.6, 128.4, 127.8, 74.3, 70.9, 60.7, 45.5, 45.3, 35.4, 32.0, 31.6, 29.8, 29.2, 23.1, 22.8, 20.9, 14.3, 14.0; MS (EI) *m/z* (rel intensity) 301 ([M-OEt]⁺, 2), 273 (0.5), 240 (15), 194 (12), 171 (5), 111 (5), 91 (100), 82 (17), 69 (16); HRMS (EI) *m/z* calculated for C₁₉H₂₅O₃ [M-OEt] 301.1804, found 301.1803.




8-(2,2-Dimethyl-propionyloxy)-3-hexyl-2-methyl-4-oxo-oct-5-enoic acid ethyl ester (6g). According to general procedure C, 550 mg (1.48 mmol) of acetal 5d and (C₆H₁₃)₂CuLi (5.1 eq.) provided 615 mg (73%) of the TBS-protected acetal: ¹H NMR δ 5.85-5.73 (m, 1 H), 5.53-5.46 (m, 1 H), 4.15-3.94 (m, 4 H), 3.94-3.80 (m, 1 H), 3.63-3.41 (m, 3 H), 2.47-2.34 (m, 3 H), 2.22-2.07 (m, 2 H), 1.6-1.5 (m, 2 H), 1.29-1.20 (m, 23 H), 0.89-0.85 (m, 12 H), 0.06-0.01 (m, 6 H). This acetal (215 mg, 0.377 mmol) with 0.250 mL (0.500 mmol) of 2.0M LDA in heptane/THF/ethylbenzene and 0.200 mL (3.22 mmol) of MeI provided 111 mg (77%) of the desired oily enone 6g: IR (neat) 2959, 2930, 2859, 1732, 1694, 1668, 1632, 1463, 1378, 1284, 1149 cm⁻¹; ¹H NMR δ 6.9-6.75 (m, 1 H), 6.23 (d, 1 H, J = 15.8 Hz), 4.20-4.00 (m, 4 H), 3.1-2.9 (m, 1 H), 2.8-2.6 (m, 1 H), 2.55 (br, 2 H), 1.65-1.55 (m, 1 H), 1.5-1.3 (m, 1 H), 1.22-1.11 (m, 20 H), 1.03 (d, 3 H, J = 6.9 Hz), 0.82 (br, 3 H); ¹³C NMR δ 202.1, 178.4, 175.7, 175.5, 143.3, 142.4, 132.5, 131.6, 62.3, 62.2, 60.6, 51.8, 51.3, 42.1, 40.2, 38.8, 32.0, 31.9, 31.6, 31.2, 29.6, 29.4, 28.1, 27.2, 26.5, 22.6, 16.0, 14.3, 14.1; MS (EI) m/z (rel intensity) 382 (M⁺, 3), 280 (4), 235 (21), 196 (34), 179 (15), 123 (16), 102 (20), 99 (95), 81 (65), 57 (100); HRMS (EI) m/z calculated for C₂₂H₃₈O₅ 382.2719, found 382.2739.




General procedure D for conjugate addition to enones (7a-g). 3,6-Dimethyl-4-oxodecanoic acid ethyl ester (7a). A suspension of 720 mg (3.51 mmol) of CuBr•SMe₂ in 10 mL of THF was treated at -78 °C with 5.00 mL (7.00 mmol) of a 1.4 M solution of MeLi in ether. The suspension was warmed to -20 °C and stirred for 20 min before recooling to -78 °C. A solution of enone **6a** (267 mg, 1.18 mmol) in 1 mL of THF was added dropwise and the temperature was raised to -30 °C. After 30 min, the reaction mixture was quenched with 10% HCl, diluted with 15 mL of EtOAc and washed with 2 N NaOH. Drying (MgSO₄), filtration and concentration yielded 276 mg (97%) of the desired oily **7a**. GC-MS analysis indicated a 1:1 mixture of diastereostereomers: IR (neat) 2959, 2929, 2874, 2859, 1736, 1714, 1460, 1409, 1393, 1377, 1341, 1272, 1187, 1148, 1100, 1030 cm⁻¹; ¹H NMR δ 4.09 (q, 2 H, *J* = 7.1 Hz), 3.0-2.8 (m, 1 H), 2.75 (dq, 1 H, *J* = 8.8, 1.7 Hz), 2.53-2.21 (m, 3 H), 2.15-1.85 (m, 1 H), 1.25-1.15 (m, 9 H), 1.08 (dd, 3 H, *J* = 7.1, 1.5 Hz), 0.87-0.82 (m, 6 H); ¹³C NMR δ 212.8, 172.5, 60.6, 48.8, 42.6, 42.3, 37.1, 36.7, 29.3, 28.8, 22.9, 19.9, 16.7, 14.3, 14.2; MS (EI) m/z (rel intensity) 242 (M⁺, 4), 197 (30), 158 (77), 143 (16), 139 (19), 127 (95), 112 (60), 69 (21), 57 (100); HRMS (EI) m/z calculated for C₁₄H₂₆O₃ 242.1882, found 242.1881.




3,6-Dibutyl-5-methyl-4-oxo-decanoic acid ethyl ester (7b). According to general procedure D, 36.0 mg (0.134 mmol) of **6b** and Bu₂CuLi (3.0 eq.) gave 35.9 mg (79%) of oily **7b** as a mixture of diastereomers upon quenching at -78 °C with 0.10 mL of MeI (12 eq.) and stirring at room for 11 h: IR (neat) 2956, 2927, 2861, 1736, 1711, 1460, 1375, 1259, 1178, 1099, 1031 cm⁻¹; ¹H NMR δ 4.10 (q, 2 H, *J* = 7.1 Hz), 3.1-3.0 and 3.0-2.9 (2m, 1 H), 2.80-2.30 (m, 3 H), 1.8-1.7 (m, 1 H), 1.7-1.55 (m, 2 H), 1.40-1.10 (m, 19 H), 1.00 (d, 3 H, *J* = 6.9 Hz), 0.95-0.87 (m, 9 H); ¹³C NMR δ 216.1, 172.7, 60.6, 48.0, 47.6, 47.4, 46.1, 38.3, 35.7, 35.2, 33.6, 32.9, 31.1, 30.7, 29.7, 29.3, 29.2, 29.0, 28.9, 23.3, 23.1, 22.8, 14.2, 14.0; MS (EI) *m/z* (rel intensity) 341 ([M+1]⁺, 3), 295 (10), 281 (6), 269 (5), 237 (7), 214 (35), 185 (100), 158 (95), 155 (55), 144 (38), 111 (35); HRMS (EI) *m/z* calculated for C₂₁H₄₀O₃ 340.2977, found 340.2991.




4-Oxo-3,6-diphenethyl-decanoic acid ethyl ester (7c). According to general procedure D, 20 mg (0.0632 mmol) of **6c** and $(PhCH_2CH_2)_2CuLi^2$ (5.5 eq.) provided 24 mg (90%) of **7c** as an oil: ¹H NMR δ 7.32-7.12 (m, 10 H), 4.14-4.06 (m, 2 H), 3.1-2.9 (m, 1 H), 2.8-2.4 (m, 7 H), 2.1-1.8 (m, 2 H), 1.7-1.5 (m, 4 H), 1.3-1.2 (m, 9 H), 0.9-0.8 (m, 3 H).



2-Benzyloxymethyl-6-butyl-3-methyl-4-oxo-decanoic acid ethyl ester (7d). According to general procedure D, 40 mg (0.115 mmol) of **6d** and Bu_2CuLi (2.1 eq.) gave 45 mg (97%) of the desired oil: ¹H NMR δ 7.36-7.27 (m, 5 H), 4.48 (s, 2 H), 4.17 (q, 2 H, *J* = 7.1 Hz), 3.67-3.62 (m, 1 H), 3.55-3.50 (m, 1 H), 3.15-3.05 (m, 1 H), 2.90-2.80 (m, 1 H), 2.5-2.3 (m, 2 H), 1.95-1.85 (m, 1 H), 1.3-1.15 (m, 15 H), 1.08 (d, 3 H, *J* = 7.0 Hz), 0.88 (2t, 6 H, *J* = 7.0 Hz).




9-Benzyloxy-3-methyl-4-oxo-6-phenyl-nonanoic acid ethyl ester (7e). According to general procedure D, 114 mg (0.358 mmol) of **6e**, Ph_2CuLi (3.4 eq.) and TMSCI (0.20 mL) gave 129 mg (91%) of the phenyl adduct **7e** upon treatment with aqueous TBAF (190 mg, 0.728 mmol): IR (neat) 3028, 2934, 2856, 1732, 1715, 1495, 1456, 1454, 1371, 1190, 1102, 1029 cm⁻¹; ¹H NMR δ 7.36-7.16 (m, 10 H), 4.44 (d, 2 H, *J* = 2.0 Hz), 4.14-4.02 (m, 2 H), 3.43-3.39 (m, 2 H), 3.25-3.15 (m, 1 H), 2.90-2.64 (m, 4 H), 2.22 (dd, 1 H, *J* = 16.7, 5.5 Hz), 1.75-1.40 (m, 4 H), 1.24 and 1.19 (2t, 3 H, *J* = 7.1 Hz), 1.09 (d, 1 H, *J* = 7.1 Hz), 0.86 (d, 1 H, *J* = 7.1 Hz); ¹³C NMR δ 211.5, 172.4, 172.2, 144.7, 144.6, 138.7, 128.6, 128.5, 127.7, 127.6, 126.4, 72.9, 70.3, 60.6, 48.9, 48.6, 42.6, 40.6, 40.5, 37.0, 36.9, 32.8, 27.8, 16.6, 16.1, 14.3; MS (EI) *m/z* (rel intensity) 396 (M⁺, 3), 351 (1), 287 (5), 259 (2), 247 (6), 221 (1), 201 (4), 147 (50), 115 (20), 91 (100); HRMS (EI) *m/z* calculated for $C_{25}H_{32}O_4$ 396.2301, found 396.2290.




6-(1-Benzyloxyethyl)-3-butyl-4-oxo-decanoic acid ethyl ester (7f). According to general protocol D, 36 mg (0.104 mmol) of **6f** with Bu_2CuLi (5.4 eq.) gave 38 mg (90%) of oily **7f**: IR (neat) 2958, 2931, 2860, 1735, 1714, 1633, 1455, 1374, 1182, 1070 cm⁻¹; ¹H NMR δ 7.34-

7.21 (m, 5 H), 4.59-4.41 (m, 2 H), 4.1-4.0 (m, 2 H), 3.6-3.5 (m, 1 H), 3.0-2.9 (m, 1 H), 2.7-2.3 (m, 4 H), 2.15-2.05 (m, 1 H), 1.6-1.1 (m, 19 H), 0.88-0.82 (m, 6 H); ¹³C NMR 212.8, 172.6, 139.2, 128.9, 128.4, 127.8, 127.5, 75.9, 75.8, 70.7, 60.6, 47.7, 47.5, 43.1, 41.0, 38.2, 38.1, 35.5, 35.3, 31.2, 30.4, 29.5, 29.2, 23.1, 22.8, 16.7, 14.3, 14.2, 14.0; MS (EI) *m/z* (rel intensity) 404 (M⁺, 0.5), 359 (5), 295 (6), 269 (10), 223 (15), 200 (20), 185 (40), 144 (17), 111 (13), 91 (100); HRMS (EI) *m/z m/z* calculated for $C_{25}H_{40}O_4$ 404.2927, found 404.2926.



3-[5-(2,2-Dimethyl-propionyloxy)-3-methyl-pentanoyl]-2-methyl-nonanoic acid ethyl ester (7g). According to general procedure D, 36 mg (0.094 mmol) of 6g and Me₂CuLi (2.2 eq.) provided 37 mg (99%) of oily 7g: ¹H NMR δ 4.17-4.02 (m, 4 H), 2.78-2.69 (m, 2 H), 2.5-2.3 (m, 2 H), 2.2-2.1 (m, 1 H), 1.7-1.6 (m, 1 H), 1.5-1.4 (m, 1 H), 1.3-1.1 (m, 22 H), 1.15-1.05 (m, 3 H), 0.96-0.92 (m, 3 H), 0.86 (t, 3 H, J = 6.8 Hz).




General procedure E for the cyclization and oxidation of ketoesters (7a-g) to pyridazinones (8a-h). 5-Methyl-6-(2-methyl-hexyl)-2*H*-pyridazin-3-one (8a). A solution of the ketoester 7a (147 mg, 0.607 mmol) in 5 mL of absolute EtOH was treated with 0.35 mL (6.1 mmol) of AcOH and 0.20 mL (6.4 mmol) of NH₂NH₂, and stirred for 15 h. After addition of 20 mL of EtOAc, the solution was washed with 10% HCI and 2 N NaOH, and dried (MgSO₄). Filtration and concentration yielded the dihydropyridazinone: ¹H NMR δ 8.30 (br, 1 H), 2.60-1.95 (m, 5 H), 1.85-1.75 (m, 1 H), 1.35-1.25 (m, 6 H), 1.15 (2d, 3 H, *J* = 7.0 Hz), 0.97-0.88 (m, 6 H).


The dihydropyridazinone intermediate was dissolved in 5 mL of MeCN and treated with 165 mg (1.23 mmol) of CuCl₂. After heating at reflux for 1 h and cooling to room temperature, the mixture was diluted with EtOAc and washed with 10% HCl followed by 2 N NaOH (3 x 15 mL). Drying (MgSO₄), filtration and concentration yielded an oil which was chromatographed on SiO₂ (hexane/EtOAc, 2:1) to give 116 mg (92%) of solid **8a**: Mp 109.2-110.6 °C; IR (CCl₄) 2956,

Page 13

2928, 2891, 2871, 2856, 1667, 778, 751 cm⁻¹; ¹H NMR δ 12.32 (s, 1 H), 6.72 (s, 1 H), 2.58 (dd, 1 H, *J* = 14.4, 5.8 Hz), 2.34 (dd, 1 H, *J* = 14.3, 8.4 Hz), 2.20 (s, 3 H), 1.95-1.80 (m, 1 H), 1.35-1.15 (m, 6 H), 0.90-0.85 (m, 6 H); ¹³C NMR δ 162.4, 148.6, 144.8, 128.0, 39.5, 36.7, 31.9, 29.3, 22.9, 19.5, 19.3, 14.1; MS (EI) *m/z* (rel intensity) 208 (M⁺, 15), 165 (10), 151 (12), 124 (100), 110 (9), 66 (7), 55 (8); HRMS (EI) *m/z* calculated for C₁₂H₂₀N₂O 208.1576, found 208.1576.




5-Butyl-6-(2-butyl-1-methyl-hexyl)-2-methyl-2H-pyridazin-3-one (8b). According to general procedure E, cyclization of **7b** (20 mg, 0.059 mmol) with 0.100 mL of MeNHNH₂ in refluxing EtOH (2 d) followed by oxidation gave 14 mg (75%) of oily **8b**: IR (neat) 2958, 2924, 2857, 1668 cm⁻¹; ¹H NMR δ 6.66 (s, 1 H), 3.74 (s, 3 H), 2.50-2.40 (m, 3 H), 1.8-1.7 (m, 1 H), 1.6-1.5 (m, 2 H), 1.5-1.35 (m, 2 H), 1.3-1.1 (m, 12 H), 1.14 (d, 3 H, *J* = 6.9 Hz), 0.97 (t, 3 H, *J* = 7.3 Hz), 0.92-0.88 (m, 6 H); ¹³C NMR δ 160.8, 151.3, 147.2, 126.5, 41.4, 39.6, 36.6, 36.5, 33.1, 30.8, 30.7, 30.5, 28.8, 23.0, 22.3, 14.1, 13.8; MS (EI) *m/z* (rel intensity) 320 (M⁺, 9), 306 (6), 263 (10), 249 (7), 194 (100), 180 (39), 165 (54), 152 (46), 138 (24); HRMS (EI) *m/z* calculated for C₂₀H₃₆N₂O 320.2828, found 320.2830.




5-Phenethyl-6-(2-phenethyl-hexyl)-2*H*-pyridazin-3-one (8c). According to general procedure E, 20 mg (0.047 mmol) of **7c** and 0.100 mL of hydrazine gave 15 mg (82%) of solid **8c**: Mp 69.1-72.4 °C; IR (neat) 2951, 2925, 2854, 1665, 1599, 1495, 1453, 1157, 1116, 1073 cm⁻¹; ¹H NMR δ 11.07 (br, 1 H), 7.35-7.11 (m, 10 H), 6.70 (s, 1 H), 2.90-2.85 (m, 2 H), 2.75-2.70 (m, 2 H), 2.65-2.50 (m, 4 H), 1.9-1.8 (m, 1 H), 1.62 (dt, 2 H, *J* = 7.8, 6.2 Hz), 1.4-1.25 (m, 6 H), 0.9-0.85 (m, 3 H); ¹³C NMR δ 161.2, 148.3, 142.4, 139.8, 128.8, 128.4, 126.8, 125.8, 36.5, 36.0, 35.2, 34.6, 33.6, 33.3, 32.9, 29.8, 28.8, 23.1, 14.2; MS (EI) *m/z* (rel intensity) 388 (M⁺, 8),

297 (8), 214 (16), 170 (6), 91 (100), 77 (6), 65 (13); HRMS (EI) m/z calculated for C₂₆H₃₂N₂O 388.2515, found 388.2523.




4-Benzyloxymethyl-6-(2-butyl-hexyl)-5-methyl-2*H***-pyridazin-3-one (8d). According to general procedure E, ketoester 7d** (20 mg, 0.049 mmol) and 0.100 mL of hydrazine provided 12 mg (66%) of solid **8d**: Mp 86.3-88.4 °C; IR (neat) 2953, 2926, 2856, 1731, 1653, 1599, 1544, 1454, 1380, 1285, 1267, 1196, 1071 cm⁻¹; ¹H NMR δ 10.40 (br, 1 H), 7.37-7.30 (m, 5 H), 4.63 (s, 3 H), 4.60 (s, 3 H), 2.49 (d, 2 H, *J* = 7.0 Hz), 2.25 (s, 3 H), 1.75-1.65 (m, 1 H), 1.29-1.26 (m, 12 H), 0.91-0.87 (m, 6 H); ¹³C NMR δ 161.4, 149.4, 144.2, 138.0, 128.6, 128.2, 128.0, 73.4, 62.4, 37.7, 36.3, 33.2, 28.8, 23.2, 15.6, 14.3; MS (EI) *m/z* (rel intensity) 264 ([M-C₇H₆O]⁺, 100), 207 (10), 169 (8), 138 (48), 91 (39), 81 (26), 69 (59), 58 (65); HRMS (EI) calculated for C₁₆H₂₈N₂O (M-C₇H₆O) 264.2202, found 264.2195; MS (CI) 371 (M⁺, 38), 264 (100).




6-(5-Benzyloxy-2-phenyl-pentyl)-5-methyl-2-benzyl-2H-pyridazin-3-one (8e). According to general procedure E, 64 mg (0.16 mmol) of **7e** and 315 mg (1.62 mmol) of BnNHNH₂•2HCI was cyclized in refluxing EtOH for 13 h, and provided upon oxidation 46 mg (0.10 mmol, 64%) of **8e**: IR (neat) 2921, 2853, 1666, 1598, 1495, 1454, 1204, 1166, cm⁻¹; ¹H NMR δ 7.34-7.17 (m, 8 H), 7.05 (d, 2 H, *J* = 6.5 Hz), 6.95 (s, 1 H), 5.26, 5.23 (AB, 2 H, *J* = 11 Hz), 4.44 (s, 2 H), 3.38 (t, 2 H, *J* = 6.4 Hz), 3.1-3.0 (m, 1 H), 2.91-2.85 (m, 2 H), 2.05 (s, 3 H), 1.85-1.70 (m, 2 H), 1.55-1.45 (m, 2 H); ¹³C NMR δ 160.5, 149.1, 144.9, 143.7, 138.6, 135.7, 128.9, 128.7, 128.5, 128.1, 127.7, 127.3, 126.7, 73.0, 70.3, 55.8, 44.1, 39.3, 32.6, 27.8, 18.8; MS (EI) *m/z* (rel intensity) 452 (M⁺, 29), 361 (43), 346 (15), 290 (15), 214 (30), 147 (100), 115 (8), 71 (42); HRMS (EI) *m/z* calculated for C₃₀H₃₂N₂O₂ 452.2464, found 452.2478. H_{3C} H_{3C} H_{3C} H_{3C} H_{3C} H_{2C} H_{2} H_{2}


6-(5-Benyloxy-2-phenyl-pentyl)-5-methyl-2-phenyl-2H-pyridazin-3-one (8f). According to general procedure E, 60 mg (0.15 mmol) of **7e** and 0.200 mL of PhNHNH₂ was cyclized in refluxing EtOH for 11 h, and provided upon oxidation 48 mg (0.10 mmol, 72%) of oily **8f**: IR (neat) 3061, 3028, 2929, 2856, 1671, 1610, 1493, 1453, 1313, 1167, 1131, 1029 cm⁻¹; ¹H NMR δ 7.40-7.25 (m, 8 H), 7.14 (d, 2 H, *J* = 6.8 Hz), 6.74 (s, 1 H), 4.45 (s, 2 H), 3.48-3.38 (m, 2 H), 3.1-2.8 (m, 3 H), 2.11 (s, 3 H), 1.95-1.75 (m, 2 H), 1.60-1.50 (m, 2 H); ¹³C NMR δ 159.9, 147.2, 143.9, 143.1, 141.6, 138.6, 129.2, 128.7, 128.5, 128.0, 127.7, 126.7, 125.5, 73.0, 70.3, 44.5, 39.6, 32.7, 27.9, 18.7; MS (EI) *m/z* (rel intensity) 438 (M⁺, 15), 347 (17), 200 (32), 147 (20), 105 (11), 91 (100), 77 (38), 65 (10); HRMS (EI) *m/z* calculated for C₂₉H₃₀N₂O₂ 438.2307, found 438.2299.




6-[2-(1-Benzyloxyethyl)-hexyl]-5-butyl-2*H***-pyridazin-3-one (8g).** According to general procedure E, 80 mg (0.20 mmol) of **7f** and 0.200 mL of hydrazine provided 59 mg (81%) of oily **8g**: IR (neat) 2956, 2929, 2870, 2861, 1666, 1597, 1463, 1455, 1378, 1110 cm⁻¹; ¹H NMR δ 12.06 (br, 1 H), 7.35-7.24 (m, 5 H), 6.68 (s, 1 H), 4.61-4.37 (m, 2 H), 3.68-3.54 (m, 1 H), 2.90-2.65 (m, 1 H), 2.67-2.30 (m, 3 H), 2.2-2.0 (m, 1 H), 1.58-1.45 (m, 2 H), 1.45-1.15 (m, 13 H), 0.97-0.84 (m, 6 H); ¹³C NMR (125 MHz) δ 162.3, 149.6, 149.3, 148.6, 148.3, 139.0, 128.3, 127.7, 127.5, 127.4, 75.5, 75.4, 70.6, 70.5, 41.6, 40.9, 32.0, 31.5, 31.4, 31.3, 30.3, 29.9, 29.5, 29.4, 23.1, 23.0, 22.4, 16.2, 14.9, 14.1, 13.9; MS (EI) *m/z* (rel intensity) 370 (M⁺, 6), 279 (75), 235 (60), 166 (43), 124 (32), 99 (62), 91 (100), 70 (23), 56 (80); HRMS (EI) *m/z* calculated for C₂₃H₃₄N₂O₂ 370.2620, found 370.2623.




2,2-Dimethyl-propionic acid 4-(4-hexyl-1,5-dimethyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-3-methyl-butyl ester (8h). According to general procedure E, 10 mg (0.025 mmol) of **7g** and 0.100 mL of MeNHNH₂ in refluxing EtOH (6 h), providing upon oxidation 7.0 mg (74%) of **8h**: IR (neat) 2959, 2928, 2873, 2855, 1729, 1646, 1596, 1481, 1462, 1285, 1158 cm⁻¹; ¹H NMR δ 4.16-4.12 (m, 2 H), 3.75 (s, 3 H), 2.62-2.37 (m, 4 H), 2.18 (s, 3 H), 2.10-2.00 (m, 2 H), 1.80-1.70 (m, 2 H), 1.60-1.50 (m, 2 H), 1.40-1.10 (m, 14 H), 0.97 (d, 3 H, *J* = 6.6 Hz), 0.95-0.88 (m, 3 H); ¹³C NMR δ 178.6, 161.2, 145.9, 142.4, 135.8, 120.6, 62.5, 40.3, 39.6, 38.8, 35.4, 31.5, 29.7, 29.6, 29.1, 29.0, 27.3, 22.6, 19.6, 14.1, 12.6; MS (El) *m/z* (rel intensity) 378 (M⁺, 37), 363 (30), 293 (45), 277 (35), 261 (20), 249 (42), 222 (18), 207 (69), 152 (30), 97 (24), 83 (28), 69 (46), 57 (100); HRMS (El) *m/z* calculated for C₂₂H₃₈N₂O₃ 378.2882, found 378.2884.




But-2-enedioic acid mono-(2-methyl-allyl) ester (9). A solution of fumaryl chloride (2.50 mL, 0.0232 mol) and 2-methyl-2-propen-1-ol (2.00 mL, 0.0238 mol) in 50 mL of dry THF at -78 °C was treated dropwise with NEt₃ (3.00 mL, 0.0215 mol) and stirred for 3 h. After dropwise addition of 1 mL of water and 3.00 mL of NEt₃, the temperature was slowly raised to -30 °C over 8 h. The mixture was poured into excess EtOAc and washed with 10% HCl, dried (MgSO₄), filtered and concentrated to provide a yellow solid that upon recrystallization from ether/hexane yielded 2.21 g (56%) of fumarate **9**: Mp 60.2-60.4 °C; IR (KBr) 3426, 3083, 1717, 1682, 1426, 1401, 1293, 1271, 1234, 1171, 1002, 911, 648, 577 cm⁻¹; ¹H NMR (DMSO-*d₆*) δ 13.21 (s, 1 H), 6.70 (s, 2 H), 4.95 (s, 1 H), 4.91 (s, 1 H), 4.57 (s, 2 H), 1.69 (s, 3 H); ¹³C NMR (MeOH-*d₄*) δ 166.3, 164.7, 139.8, 134.2, 132.8, 112.3, 68.0, 18.2; MS (EI) *m/z* (rel intensity) 170 (M⁺, 0.2), 152 (0.6), 99 (100), 81 (24), 72 (74), 55 (31); HRMS (EI) *m/z* calculated for C₈H₈O₃ (M – H₂O) 152.0473, found 152.0470.



But-2-enedioic acid 2-methyl-oxiranylmethyl ester 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octyl ester (10). A solution of fumaric acid 9 (740 mg, 4.35 mmol) and 1H,1H,2H,2H-perfluorooctanol (1.00 mL, 4.53 mmol) in 10 mL of CH₂Cl₂ at 0 °C was treated with DCC (1.10 g, 5.34 mmol) followed by DMAP (28 mg, 0.23 mmol). The reaction mixture was stirred at room temperature for 8 h, filtered, washed with 10% HCl, 2 N NaOH, and finally dried (MgSO₄). The suspension was filtered, concentrated, and redissolved in 10 mL of CH₂Cl₂. At 0 °C, mCPBA (2.95 g, 8.58 mmol for a 50% purity) was added and the mixture was stirred overnight at 5 °C, quenched with saturated Na₂S₂O₃, stirred for 30 min, and washed with 2 N NaOH. Drying (MgSO₄), filtration, and concentration followed by chromatography on SiO₂ (EtOAc/hexane, 1:9) provided 1.92 g (83%) of oily 10: ¹H NMR δ 6.91, 6.90 (AB, 2 H, *J* = 16.1 Hz), 4.52 (t, 2 H, *J* = 6.4 Hz), 4.39 (d, 1 H, *J* = 12.0 Hz), 4.09 (d, 2 H, *J* = 12.0 Hz), 2.80 (d, 1 H, *J* = 4.6 Hz), 2.71 (d, 1 H, *J* = 4.6 Hz), 2.54 (tt, 2 H, *J* = 18.2, 6.4 Hz) 1.42 (s, 3 H); MS (EI) *m/z* (rel intensity) 445 ([M-C₄H₇O₂]⁺, 100), 169 (5), 99 (23), 71 (26); HRMS (EI) *m/z* calculated for C₁₂H₆O₃F₁₃ 445.0109, found 445.0103.



(2S,4S),(2R,4R)-3-[(2-Hex-1-(*E*)-enyl)-4-hydroxymethyl-4-methyl-[1,3]dioxolan-2yl)]-acrylic acid 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octyl ester (11). According togeneral procedure A with 10% (PhO)₃P and an additional 5 mol% Ag(I) added after 5 h, 135 mg(0.254 mmol) of 10 and 0.050 mL (0.435 mmol) of hexyne of provided 72 mg (46%) of oily 11 as $a ca. 2:1 mixture of diastereomers. Major isomer: ¹H NMR <math>\delta$ 6.88 (d, 1 H, *J* = 15.4 Hz), 6.14 (d, 1 H, *J* = 15.3 Hz), 5.90 (dt, 1 H, *J* = 15.7, 6.7 Hz), 5.52 (d, 1 H, *J* = 15.4 Hz), 4.48 (t, 2 H, *J* = 6.5 Hz), 4.05 (d, 1 H, *J* = 8.4 Hz), 3.66 (d, 1 H, *J* = 8.4 Hz), 3.48-3.59 (m, 2 H), 2.54 (tt, 2H, *J* = 18.4, 6.3 Hz), 2.07 (dt, 2 H, *J* = 6.9, 6.8 Hz), 1.40-1.20 (m, 10 H), 0.87 (t, 3 H, *J* = 6.9 Hz); MS (EI) *m/z* (rel intensity) 616 (M⁺, 4), 585 (84), 533 (33), 445 (42), 264 (27), 253 (39), 225 (100), 199 (59), 130 (96), 111 (50), 71 (65), 57 (50); HRMS (EI) *m/z* calculated for C₂₂H₂₅O₅F₁₃ 616.1494, found 616.1465.



5-Methyl-6-(2-methyl-hexyl)-4,5-dihydro-2H-pyridazin-3-one (13). A suspension of CuBr•SMe₂ (100 mg, 0.486 mmol) in 2 mL of THF at -30 °C was treated with 0.700 mL of a 1.4 M (0.98 mmol) MeLi/ether solution and warmed slowly to 0 °C. After turning homogeneous, the solution was cooled to -78 °C and TMSCI (0.100 mL, 0.789 mmol) was added followed by a solution of the acetal **11** (61 mg, 0.099 mmol) in 1 mL of THF. The yellow solution was warmed to -30 °C over 1 h, then stirred for an additional 1 h before quenching with 1 mL of saturated NaHCO₃ and filtering through a pad of SiO₂. The mixture was concentrated, poured into 2 mL of MeOH and 1 mL of water, and extracted five times with excess FC-72. The combined FC-72 layers were dried (MgSO₄), filtered and concentrated *in vacuo* to give 57 mg of crude acetal.


A solution of this acetal in 3 mL of acetone/water (10:1) was treated with TsOH (4.1 mg, 0.0216 mmol) and heated at reflux for 9 h. The reaction mixture was treated with 1 mL of saturated NaHCO₃ solution, filtered through a pad of SiO₂, and concentrated. The oily residue was dissolved in MeOH/water and extracted 5 times with excess FC-72. The combined fluorous layers were dried (MgSO₄), and concentrated *in vacuo*. Dilution of the MeOH/water layer with water and extraction with EtOAc indicated no desired compound remained. The crude enone was dissolved in 1 mL of THF for the next step.


A suspension of CuBr•SMe₂ (44 mg, 0.214 mmol) in 1 mL of THF was treated at -30 °C with 1.4 M MeLi/ether (0.300 mL, 0.420 mmol), warmed to 0 °C and stirred until homogeneous. Upon recooling to -78 °C, the enone solution was added and the mixture was stirred for 4 h, quenched with water, filtered through a plug of SiO₂, concentrated and dissolved in MeOH/water. After FC-72 extraction (5 times), drying (MgSO₄) and removal of the fluorous solvent *in vacuo* provided 42 mg (76%) of the fluorous keto-ester. This material was slightly impure by TLC analysis. A sample was chromatographed on SiO₂ (EtOAc/hexane, 1:20) to give pure **12**: IR (neat) 2960, 2930, 1744, 1714, 1659, 1642, 1240, 1204, 1145, 1081 cm⁻¹; ¹H NMR & 4.37 (t, 2 H, *J* = 6.6 Hz), 3.05-2.95 (m, 1 H), 2.96-2.75 (m, 1 H), 2.55-2.25 (m, 5 H), 2.1-2.0 (m, 1 H), 1.3-1.1 (m, 6 H), 1.14 (2d, 3 H, *J* = 7.1 Hz), 0.91-0.86 (m, 6 H); ¹³C NMR (125 MHz) & 212.5, 172.1, 118.4-108.4 (m), 56.4, 48.6, 42.6, 42.2, 36.7, 36.6, 36.5, 30.7, 30.5, 30.3, 29.3, 29.2, 28.8, 22.9, 19.9, 16.7, 16.6, 14.1; MS (EI) *m/z* (rel intensity) 560 (M⁺, 6), 541 (3), 503 (11), 476 (68), 461 (28), 391 (36), 197 (70), 139 (31), 127 (97), 112 (62), 69 (39), 57 (100); HRMS (EI) *m/z* calculated for C₂₀H₂₅O₃F₁₃ 560.1596, found 560.1610.


A solution of the crude keto-ester **12** (18 mg, 0.032 mmol) in 1 mL of absolute EtOH was stirred for 23 h in the presence of hydrazine (0.10 mL) and AcOH (0.17 mL). The mixture was

poured into 3 mL of EtOAc, washed with 10% HCl, 2 N NaOH, and brine, dried (MgSO₄) and filtered. The solution was concentrated to an oily residue and suspended in MeCN, then washed five times with excess FC-72. The MeCN layer was concentrated to give the desired dihydropyridazinone **13** (5.8 mg, 66%) in 98.7% purity (GC-MS): ¹H NMR δ 8.21 (s, 1 H), 2.6-1.9 (m, 5 H), 1.85-1.75 (m, 1 H), 1.35-1.25 (m, 6 H), 1.16 (2d, 3 H, *J* = 7.3 Hz), 0.97-0.89 (m, 6 H); MS (EI) *m/z* (rel intensity) 210 (M⁺, 12), 195 (2), 167 (4), 153 (11), 126 (100), 111 (6), 91 (6), 69 (12), 55 (10); HRMS (EI) *m/z* calculated for C₁₂H₂₂N₂O 210.1732, found 210.1726.













































































Page 44














Page 47
















































Page 61

